Literature DB >> 14635048

IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptor beta1 deficiency.

Marieke A Hoeve1, Tjitske de Boer, Dennis M L Langenberg, Ozden Sanal, Frank A W Verreck, Tom H M Ottenhoff.   

Abstract

IFN-gamma and IL-12 are crucial cytokines for cell-mediated immunity against intracellular pathogens. We have previously shown that human IL-12Rbeta1-deficiency leads to impaired IL-12 responsiveness and unusual susceptibility to infections due to mycobacteria and salmonellae. IL-23 is a cytokine with functions that partially overlap with those of IL-12. IL-23 consists of IL-12p40 and a novel p19 protein, and binds to a receptor complex comprising IL-12Rbeta1 and IL-23R. Thus, IL-12Rbeta1-deficiency may impair both IL-12- and IL-23 signaling, and both may contribute to the immunological phenotypes. To examine whether IL-12Rbeta1 is essential for IL-23 signaling in human T cells, we have studied IL-23 responsiveness of four IL-12Rbeta1-deficient individuals. Whereas IL-23 promoted IFN-gamma production by CD4(+) and CD8(+) T cells in controls, IL-12Rbeta1-deficient T cells lacked IL-23-induced IFN-gamma secretion, but responded normally to IL-2, IL-4, IL-15 and IL-18. We also show that induction of IFN-gamma production by IL-23 depends upon TCR-ligation and is enhanced by CD28-costimulation. Furthermore, IL-23 cooperates with IL-12 and IL-18 in promoting IFN-gamma production in controls, but not in patients. We conclude that IL-12Rbeta1-deficiency impairs IL-12- and IL-23-dependent signaling in human T cells. The syndrome caused by IL-12Rbeta1-deficiency thus needs to be reinterpreted as resulting from defective IL-12-as well as IL-23-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14635048     DOI: 10.1002/eji.200324343

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Identification and expression analysis of alternatively spliced isoforms of human interleukin-23 receptor gene in normal lymphoid cells and selected tumor cells.

Authors:  Xiang-Yue Zhang; Hai-Jing Zhang; Yun Zhang; Ying-Jie Fu; Jie He; Li-Ping Zhu; Shu-Hui Wang; Li Liu
Journal:  Immunogenetics       Date:  2005-12-22       Impact factor: 2.846

2.  IL12Rβ1ΔTM is a secreted product of il12rb1 that promotes control of extrapulmonary tuberculosis.

Authors:  Aurelie A Ray; Jeffrey J Fountain; Halli E Miller; Andrea M Cooper; Richard T Robinson
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

3.  The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects.

Authors:  Osamu Shimozato; Shin-ichi Ugai; Masako Chiyo; Hisanori Takenobu; Hiroyasu Nagakawa; Akihiko Wada; Kiyoko Kawamura; Hiroshi Yamamoto; Masatoshi Tagawa
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

4.  Influenza virus vaccination induces interleukin-12/23 receptor beta 1 (IL-12/23R beta 1)-independent production of gamma interferon (IFN-gamma) and humoral immunity in patients with genetic deficiencies in IL-12/23R beta 1 or IFN-gamma receptor I.

Authors:  Tjitske de Boer; Jaap T van Dissel; Taco W J Kuijpers; Guus F Rimmelzwaan; Frank P Kroon; Tom H M Ottenhoff
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

Review 5.  IL-23 and IL-17 in tuberculosis.

Authors:  Shabaana A Khader; Andrea M Cooper
Journal:  Cytokine       Date:  2008-01-22       Impact factor: 3.861

6.  Impaired IL-12- and IL-23-Mediated Immunity Due to IL-12Rβ1 Deficiency in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease.

Authors:  Nioosha Nekooie-Marnany; Caroline Deswarte; Vajiheh Ostadi; Bahram Bagherpour; Elaheh Taleby; Mazdak Ganjalikhani-Hakemi; Tom Le Voyer; Hamid Rahimi; Jérémie Rosain; Zahra Pourmoghadas; Saba Sheikhbahaei; Razieh Khoshnevisan; Daniel Petersheim; Daniel Kotlarz; Christoph Klein; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Jacinta Bustamante; Roya Sherkat
Journal:  J Clin Immunol       Date:  2018-09-25       Impact factor: 8.317

7.  A 475 years-old founder effect involving IL12RB1: a highly prevalent mutation conferring Mendelian Susceptibility to Mycobacterial Diseases in European descendants.

Authors:  J Yancoski; C Rocco; A Bernasconi; M Oleastro; L Bezrodnik; C Vrátnica; F Haerynck; S D Rosenzweig
Journal:  Infect Genet Evol       Date:  2009-03-09       Impact factor: 3.342

8.  Tuberculosis endotypes to guide stratified host-directed therapy.

Authors:  Andrew R DiNardo; Tomoki Nishiguchi; Sandra L Grimm; Larry S Schlesinger; Edward A Graviss; Jeffrey D Cirillo; Cristian Coarfa; Anna M Mandalakas; Jan Heyckendorf; Stefan H E Kaufmann; Christoph Lange; Mihai G Netea; Reinout Van Crevel
Journal:  Med (N Y)       Date:  2021-01-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.